Evidence map›Paper›PMID 28728596›Full record

ReviewJournal of translational medicine2017

Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives.

Alexander Vaiserman, Oleh Lushchak

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Vaccine hesitancy in patients with COVID-19 who have back pain.Osong public health and research perspectives · 2023
    Article
  6. The Funding Channels of Geroscience.Cold Spring Harbor perspectives in medicine · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.Advances in experimental medicine and biology · 2021
    Article
  11. Article
  12. Review
  13. Phenotypic Screening inPharmaceuticals (Basel, Switzerland) · 2020
    Review
  14. Review
  15. Article
  16. Review
  17. Anise HyssopFrontiers in physiology · 2020
    Article
  18. Review
  19. Aging: therapeutics for a healthy future.Neuroscience and biobehavioral reviews · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexander VaisermanLaboratory of Epigenetics, Institute of Gerontology, Vyshgorodskaya St. 67, Kiev, 04114, Ukraine. vaiserman23@gmail.com.ORCID 0000-0003-0597-0439
Oleh LushchakDepartment of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost modern societies undergo rapid population aging. The rise in life expectancy, nevertheless, is not accompanied, to date, by the same increment of healthspan. Efforts to increase healthspan by means of supplements and pharmaceuticals targeting aging-related pathologies are presently in spotlight of a new branch in geriatric medicine, geroscience, postulating that aging could be manipulated in such a way that will in parallel allow delay the onset of all age-associated chronic disorders. DISCUSSION: Currently, the concept of the "longevity dividend" has been developed pointed out that the extension of healthspan by slowing the rate of aging is the most efficient way to combat various aging-related chronic illnesses and disabling conditions than combating them one by one, what is the present-day approach in a generally accepted disease-based paradigm. The further elaboration of pharmaceuticals specifically targeted at age-associated disorders (commonly referred to as 'anti-aging drugs') is currently one of the most extensively developed fields in modern biogerontology. Some classes of chemically synthesized compounds and nutraceuticals such as calorie restriction mimetics, autophagy inductors, senolytics and others have been identified as having potential for anti-aging intervention through their possible effects on basic processes underlying aging. In modern pharmaceutical industry, development of new classes of anti-aging medicines is apparently one of the most hopeful directions since potential target group may include each adult individual. Implementation of the geroscience-based approaches into healthcare policy and practice would increase the ratio of healthy to unhealthy population due to delaying the onset of age-associated chronic pathologies. That might result in decreasing the biological age and increasing the age of disability, thus increasing the age of retirement and enhancing income without raising taxes. Economic, social and ethical aspects of applying the healthspan- and lifespan-promoting interventions, however, have to be comprehensively debated prior to their implementation in public health practice.

Indexed as

Dietary SupplementsPublic Health PracticeGeriatricsHumansLongevityUnited StatesUnited States Food and Drug AdministrationAgingAnti-aging drugsGeroscienceHealthspanLife extensionLongevity dividend

Identifiers

PMID28728596
PMCPMC5520340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.